– USA, NJ – Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced the appointment of Jan De Witte as its next President and CEO, succeeding Peter Arduini, who will step down as CEO.
“We are thrilled to have Jan join Integra at this exciting time in the company’s history. Jan is a proven global business leader with extensive C-level experience at internationally-recognized companies. His deep experience in healthcare and technology, commitment to advancing sustainability and proven ability to develop and commercialize innovative new products led the board to select Jan as Integra’s next CEO. His values around inclusivity, integrity and accountability are highly aligned with Integra’s people-first culture. We look forward to Jan’s start later this year and his many future contributions to Integra,” said Board Chairman, Stuart Essig.
Mr. De Witte will join Integra before the end of the year, at which time he will also be appointed to its board of directors.
About Jan D. De Witte
With over two decades in the healthcare industry, Jan De Witte brings global public company leadership experience as well as deep technological, operational, and commercial expertise to Integra. For the past five years, De Witte served as CEO of Barco N.V. (EBR: BAR), where he created shareholder value through digital innovation and new product development, commercial acceleration, international market growth, and operational excellence while effectively leading the company through the COVID-19 pandemic. In addition, De Witte spent 17 years in senior-level leadership roles at GE, including serving as President and CEO of GE Global Healthcare IT, where he had full global P&L responsibility for product management, technology and software development, commercialization, services, and solutions delivery. Before GE, De Witte spent five years in strategic consulting at McKinsey and three years in operations at Procter & Gamble.
De Witte currently serves on the Board of Directors of ResMed (NYSE: RMD | ASX: RMD), a global leader in digital health technologies and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases.
Mr. De Witte commented, “I am honored and excited to be joining Integra and a very talented and dedicated team. The company has a rich history of global leadership in neurosurgery with some of the most recognized brands in plastic and reconstructive surgery. I look forward to building on an already strong foundation to drive value for all our stakeholders. To the 3,700 employees around the world, I am delighted to join such an engaged and entrepreneurial culture and look forward to working with you to further elevate Integra’s impact around the world.”
Mr. De Witte holds a master’s of science degree in electromechanical engineering with the greatest distinction from the KU Leuven in Belgium and a master’s degree in business administration from Harvard University. He has lived and worked in seven countries, with much of his career spent in the U.S., and is fluent in three languages. He is also a dedicated community leader.
About Integra LifeSciences
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel, Bactiseal, CerebroFlo, CereLink Certas Plus, Codman, CUSA, Cytal, DuraGen, DuraSeal, Gentrix, ICP Express, Integra, MatriStem UBM, MAYFIELD, MediHoney, MicroFrance, MicroMatrix, PriMatrix, SurgiMend, TCC-EZ, and VersaTru.
For more information: https://www.integralife.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
